Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy
Authors:
- 10 August 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 48 (9) , 1001-1007
Abstract
Objectives: The severe acute respiratory syndrome coronavirus 2 (COVID-19) outbreak in Italy, especially in Lombardy and Bergamo city, represented probably nowadays one of the first major clusters of COVID-19 in the world. The aim of this report is to describe the activity of Bergamo Teratology Information Service (TIS) in supporting the public and health-care personnel in case of drug prescriptions in suspected/confirmed COVID-19 pregnant and lactating patients during COVID-19 outbreak in Italy. Methods: All Bergamo TIS requests concerning COVID-19 pregnant and lactating women have been retrospectively evaluated from 1 March to 15 April 2020. Type of medications, drug’s safety profile and compatibility with pregnancy and lactation are reported. Results: Our service received information calls concerning 48 (9 pregnant, 35 lactating) patients. Among pregnant and lactating women, the requests of information were related to 16 and 60 drugs prescriptions respectively. More than half concerned drugs prescriptions during the first and second trimester (13/16) and during the first six months of lactation (37/60). Hydroxychloroquine and azithromycin were the most involved. Conclusions: Hydroxychloroquine and azithromycin at dosages used for COVID-19 may be considered compatible and reasonably safe either in pregnancy and lactation. Antivirals may be considered acceptable in pregnancy. During lactation lopinavir and ritonavir probably exhibit some supportive data from literature that darunavir and cobicistat do not. Tocilizumab may be considered for COVID-19 treatment because no increased malformation rate were observed until now. However caution may be advised because human data are limited and the potential risk of embryo-fetal toxicity cannot be excluded.Keywords
This publication has 29 references indexed in Scilit:
- Antiretroviral Pharmacokinetics in Mothers and Breastfeeding Infants from 6 to 24 Weeks Post-Partum: Results of the Ban StudyAntiviral Therapy, 2013
- Clarithromycin in Early Pregnancy and the Risk of Miscarriage and Malformation: A Register Based Nationwide Cohort StudyPLOS ONE, 2013
- Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and SafetyAntiviral Therapy, 2012
- Maternal Exposure to Amoxicillin and the Risk of Oral CleftsEpidemiology, 2012
- Maternal use of antibiotics and the risk of orofacial clefts: a nationwide cohort studyPharmacoepidemiology and Drug Safety, 2011
- Lopinavir/Ritonavir in PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseasesPediatric Rheumatology, 2009
- Pregnancy outcome after gestational exposure to the new macrolides: A prospective multi-center observational studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2008
- A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomesAmerican Journal of Obstetrics and Gynecology, 2008
- Accumulation of Chorio-retinotoxic Drugs in the Foetal EyeNature, 1970